Annapolis Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Annapolis Financial Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$526	Buy	+1	New	+$1.11K	﹤0.01%	397

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Annapolis Financial Services's REGN Position: Q3 2024 in Review

Annapolis Financial Services opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2024: 1 share worth $526. The stake represents ﹤0.01% of the portfolio and ranks #397 among its holdings.

1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

Annapolis Financial Services held 1 share of Regeneron Pharmaceuticals worth $526 as of Q3 2024.
Regeneron Pharmaceuticals was a new Annapolis Financial Services position in Q3 2024.
Regeneron Pharmaceuticals made up ﹤0.01% of Annapolis Financial Services's portfolio in Q3 2024, its #397 holding.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Annapolis Financial Services's 13F filing for Q3 2024, filed 16 Oct 2024.